Esperion Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Esperion Therapeutics, Inc. (ESPR) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-51.75-209.25-233.66-269.11-143.55-97.17-201.81
Depreciation & Amortization0.060.160.500.610.550.100.27
Stock Based Compensation11.9911.9615.2224.3128.390.000.00
Change in Working Capital-60.5313.68-3.37-52.51-4.26-7.3029.16
Change in Accounts Receivable-31.65-14.77-10.80-10.55-12.390.000.00
Change in Inventory-28.87-30.42-0.81-18.26-16.140.000.00
Change in Accounts Payable12.438.685.60-34.1023.110.000.00
Change in Other Working Capital-12.4548.3846.2135.531.650.000.00
Other Operating Activities76.5748.3846.2135.5319.5634.000.00
Net Cash from Operating Activities-23.65-135.49-174.83-263.81-85.18-70.34-148.64
Investing Activities
Capital Expenditures-0.320.000.000.00-0.870.95-0.15
Purchases of Investments0.0042.50-59.90-50.4834.730.000.00
Sales/Maturities of Investments0.0042.5068.00-50.48-12.5065.18140.60
Other Investing Activities0.000.000.000.00-12.500.000.00
Net Cash from Investing Activities-0.3242.508.10-50.4821.3664.23140.45
Financing Activities
Debt Repayment35.010.000.00-0.44-8.410.00-1.05
Common Stock Issued91.1956.8890.85218.696.630.000.00
Common Stock Repurchased0.000.00-50.000.00-55.000.000.00
Other Financing Activities-39.720.02-50.2249.60-29.91124.420.00
Net Cash from Financing Activities86.4850.4632.61268.22201.73136.2010.69
Summary
Net Change in Cash62.51-42.53-134.12-46.07137.90130.092.51
Cash at Beginning of Period82.25124.78258.89304.96167.0636.9734.47
Cash at End of Period144.7682.25124.78258.89304.96167.0636.97
Free Cash Flow-23.97-135.49-174.83-263.81-86.05-71.29-148.79
Supplemental Disclosures
Interest Paid5.8315.518.020.000.000.000.00